Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary

   Annual General Meeting Schedules, New Drug Applications, Positive Study
Results, Conference Participations, and Secondary Offerings - Research Report
              on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis

PR Newswire

NEW YORK, December 5, 2013

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Mindray
Medical International Limited (NYSE: MR), AcelRx Pharmaceuticals, Inc.
(NASDAQ: ACRX), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), ZELTIQ
Aesthetics, Inc. (NASDAQ: ZLTQ), and Clovis Oncology, Inc. (NASDAQ: CLVS).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Mindray Medical International Limited Research Report

On November 26, 2013, Mindray Medical International Limited (Mindray)
announced that it will host its 2013 annual general meeting of record at the
Company's Hong Kong office on December 17, 2013 at 11:00 a.m. Beijing/Hong
Kong Time (December 16, 2013 at 10:00 p.m. US ET). Mindray reported that the
shareholder record date is November 12, 2013. In addition, Mindray informed
that its Form 20-F and proxy materials are accessible through the Investor
Relations website. The Full Research Report on Mindray Medical International
Limited - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8d4d_MR

--

AcelRx Pharmaceuticals, Inc. Research Report

On December 2, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that its
Zalviso New Drug Application (NDA) was accepted for filing by the FDA on
November 26, 2013. Richard King, President and CEO of AcelRx commented, "We
are extremely pleased with the filing of our NDA for Zalviso, representing
achievement of another critical milestone for AcelRx. Zalviso, if approved,
will provide hospitalized patients with a non-programmable, non-invasive,
patient-controlled treatment option for the management of moderate-to-severe
acute pain with a rapid onset of pain relief compared to the commonly used,
intravenous patient controlled analgesia systems that typically utilize
morphine." The Full Research Report on AcelRx Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1454_ACRX

--

Merrimack Pharmaceuticals, Inc. Research Report

On November 26, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) announced
results of two Phase 2 studies evaluating MM-121 in the treatment of women
with ER/PR+, HER2 negative breast cancer. Merrimack reported that the MM-121
is a monoclonal antibody designed to target the ErbB3 (HER3) receptor and to
interfere with growth factor-mediated resistance to standard-of-care
therapies. According to Merrimack, one study was conducted in metastatic
breast cancer (mBC) in combination with exemestane, while the second study was
conducted in the neoadjuvant setting in combination with paclitaxel followed
by doxorubicin and cyclophosphamide. The Full Research Report on Merrimack
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8bb0_MACK

--

ZELTIQ Aesthetics, Inc. Research Report

On December 2, 2013, ZELTIQ Aesthetics, Inc. (ZELTIQ) announced that the
Company is participating at the upcoming J.P. Morgan SMid Cap Conference at
The Westin River North in Chicago on December 11, 2013. According to ZELTIQ,
Patrick F. Williams, Senior Vice President and CFO of the Company is scheduled
to present at the conference at approximately 8:00 a.m. CT. ZELTIQ also
informed that the audio webcast of the Company's presentation and its replay
will be available for 90 days at its Investor Relations website. The Full
Research Report on ZELTIQ Aesthetics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/b15b_ZLTQ

--

Clovis Oncology, Inc. Research Report

On December 2, 2013, Clovis Oncology, Inc. (Clovis) announced that certain
selling stockholders have commenced an underwritten public offering of 2
million shares of the Company's common stock, which they recently acquired as
consideration in connection with Clovis' acquisition of EOS (Ethical Oncology
Science) S.p.A. Clovis reported that the net proceeds from the sale will be
received by the selling stockholders and not by the Company, and the total
number of shares of its outstanding common stock will not change as a result
of the offering. Clovis also informed that the selling stockholders intend to
grant J.P. Morgan Securities LLC, the sole manager for the offering, a 30-day
option to purchase up to an additional 15% of the number of shares sold to
cover over-allotments, if any. The Full Research Report on Clovis Oncology,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/6a2a_CLVS

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.